Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) is a provider of injectable solutions and services that support the containment and delivery of medicines for pharmaceutical, biotechnology and generic drug companies. News related to WST often centers on its role in injectable drug administration, its proprietary product platforms and its contract manufacturing activities.
Company announcements frequently include quarterly and annual financial results, updates to revenue and earnings guidance, and details on performance in its Proprietary Products and Contract-Manufactured Products segments. Releases have highlighted trends in High-Value Product Components and High-Value Product Delivery Devices, as well as demand for self-injection devices for therapeutic areas such as obesity and diabetes.
West’s news flow also covers product and technology developments. Recent examples include the launch of the West Synchrony™ Prefillable Syringe System, described as a system-level solution for biologics and vaccines, and updates on the SmartDose® on-body delivery platform. The company has announced a definitive agreement to sell manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie, along with related information on continued supply and ongoing project commitments.
Investors following WST news will also see disclosures about capital allocation, such as dividends and share repurchases, as well as governance and leadership changes reported via press releases and Form 8-K filings. Conference participation and investor presentations are regularly announced, providing additional context on the company’s strategy and financial outlook. This news page aggregates such updates so readers can review West’s latest reported developments, financial communications and product-related announcements in one place.
West (NYSE: WST) will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, followed by a conference call at 8:00 a.m. Eastern Time. A live webcast, slide presentation and 90-day replay will be available on the company's investor website.
West Pharmaceutical Services (NYSE: WST) announced the global commercial availability of the West Synchrony™ S1 prefillable syringe (PFS) system at Pharmapack 2026 in Paris on January 20, 2026. The system offers 1 ml long and 2.25 ml staked needle options for biologics, plus 1 ml standard staked needle and Luer lock options for vaccines, with rigid or soft needle shields and integrated tip caps. The platform includes West NovaPure® and FluroTec™ barrier film plungers. West will present learning labs and a product gallery at Pharmapack on January 21–22, 2026 to highlight integrated solutions and combination-product support.
AbbVie (NYSE:ABBV) agreed to acquire a device manufacturing facility and associated intellectual property from West Pharmaceutical Services (NYSE:WST) in Tempe, Arizona, expanding its drug delivery device manufacturing capacity.
AbbVie plans to hire approximately 200 employees at the site and to invest more than $175 million to acquire, modernize, and integrate the facility into its global network. The deal transfers multiple production lines and 3.5 mL on-body injector technology to support current and next-generation immunology and neuroscience medicines. The transaction is anticipated to close in mid-2026, subject to closing conditions, and is part of AbbVie's broader plan to invest >$10 billion in U.S. capital over the next decade.
West (NYSE: WST) agreed to sell all manufacturing and supply rights for the SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for $112.5 million at close, subject to working capital and other adjustments.
The definitive agreement is subject to closing conditions and is expected to close in mid-2026. West will continue commercial supply and execute ongoing project commitments prior to close, which may include milestone-based payments before closing.
SmartDose 3.5mL revenues represented approximately 4% of fiscal 2025 revenue. West said it will provide more details when it issues 2026 guidance on its Q4 2025 earnings call in February. The company will continue development and manufacture of other SmartDose products, including the SmartDose 10mL system.
West Pharmaceutical Services (NYSE: WST) will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:00 am PST in San Francisco.
The presentation will be available via a live webcast accessible in the Investors section of the company website, with a replay available on the website for approximately 90 days after the event.
West (NYSE: WST) declared a regular quarterly dividend of $0.22 per share on its common stock.
The board declared the dividend on December 9, 2025; it is payable on February 4, 2026 to shareholders of record on January 28, 2026.
West Pharmaceutical Services (NYSE: WST) launched the West Synchrony™ Prefillable Syringe (PFS) System at CPHI Worldwide and said the system will be commercially available in January 2026. The system is described as a fully verified, system-level solution for biologics and vaccines that provides a single design verification and characterization package, a single system-level drug master file and regulatory package, and single-source supply options with make-to-stock and make-to-order and low minimum order quantities.
Management positioned the offering as intended to streamline syringe selection, accelerate regulatory submissions, and secure supply chains, while also cautioning that forward-looking statements contain risks and that there is no certainty the product will achieve particular results.
West Pharmaceutical Services (NYSE: WST) will present at four upcoming investor conferences in November–December 2025. Scheduled appearances include a UBS Global Healthcare fireside chat at 9:30 AM ET on Nov 11, 2025 in Palm Beach Gardens, FL; Jefferies Global Healthcare at 10:00 AM GMT on Nov 18, 2025 in London, UK; Stephens Annual Investment Conference at 11:00 AM CT on Nov 20, 2025 in Nashville, TN; and Citi Global Healthcare at 2:30 PM ET on Dec 2, 2025 in Miami, FL.
The company said live webcasts for each event will be available in the Investors section of the company website, and replays will be accessible for approximately 90 days after each event.
West (NYSE: WST) reported Q3 2025 net sales of $804.6M, up 7.7% (organic +5.0%), and diluted EPS of $1.92 (adjusted-diluted EPS $1.96).
Management raised full-year 2025 guidance to $3.060B–$3.070B net sales and adjusted-diluted EPS to $7.06–$7.11. Q4 guidance introduced: net sales $790M–$800M and adjusted-diluted EPS $1.81–$1.86.
Segment highlights: HVP Components +16.3% (48% of sales), HVP Delivery Devices down 15.7% (one-time $19M 2024 incentive), Proprietary Products and Contract Manufacturing both grew. Nine-month cash flow metrics improved with free cash flow $293.9M.
West (NYSE: WST) will release third-quarter 2025 financial results before the market opens on Thursday, October 23, 2025 and will host a conference call the same day at 8:00 a.m. ET.
The event includes a live webcast, a slide presentation posted in the Investors section of the company website on the day of the call, and a replay available for about 90 days. Participants who wish to ask questions must register in advance to receive a dial-in number and unique PIN for question submission.
FAQ
What is the current stock price of West Pharm Svcs (WST)?
What is the market cap of West Pharm Svcs (WST)?
